Related Experiment Video

Updated: Jul 11, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma

Saar Gill1, Jeremy Shapiro, David Westerman

  • 1Department of Oncology, Cabrini Medical Centre, Malvern, Australia.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|October 2, 2007
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Related Experiment Videos

Last Updated: Jul 11, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

The Development of Non-Tuberculosis Mycobacterial Infections in Sézary Syndrome: A Case Report of Two Patients.

The Australasian journal of dermatology·2026

Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

Advances in therapy·2026

Impact of Immunotherapy Prescribing Restrictions on Time to Systemic Therapy and Outcomes in Metastatic Clear Cell Renal Carcinoma in Australia.

Asia-Pacific journal of clinical oncology·2026

Consensus recommendations for technical standardization of flow cytometric measurable residual disease assessment in B-cell acute lymphoblastic leukemia: A report from The Cytometry Society, India.

Cytometry. Part B, Clinical cytometry·2026

Breast implant associated anaplastic large cell lymphoma is a heterogeneous T cell disease with active pro-tumour cross-talk and immune suppression.

Leukemia·2026

Artificial Intelligence-Assisted Risk Stratification in Stage II Colorectal Cancer: Multi-Institutional Validation of Semantically Enhanced Deep Learning.

Gastroenterology·2026

RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Prognostic Impact of Telomere Maintenance Mechanisms in Neuroblastoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Clinical Practice Guideline for Systemic Antibacterial and Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Cell Transplant Recipients: 2026 Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.3.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us